These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Weckbecker G; Liu R; Tolcsvai L; Bruns C Cancer Res; 1992 Sep; 52(18):4973-8. PubMed ID: 1325289 [TBL] [Abstract][Full Text] [Related]
3. [The role of somatostatin analogues in the treatment of hypophyseal adenomas]. Losa M; Mortini P; Giovanelli M Minerva Endocrinol; 2003 Mar; 28(1):39-51. PubMed ID: 12621362 [TBL] [Abstract][Full Text] [Related]
4. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. Lamberts SW; Hofland LJ; van Koetsveld PM; Reubi JC; Bruining HA; Bakker WH; Krenning EP J Clin Endocrinol Metab; 1990 Sep; 71(3):566-74. PubMed ID: 2168430 [TBL] [Abstract][Full Text] [Related]
5. From somatostatin to sandostatin: pharmacodynamics and pharmacokinetics. Marbach P; Briner U; Lemaire M; Schweitzer A; Terasaki T Metabolism; 1992 Sep; 41(9 Suppl 2):7-10. PubMed ID: 1355590 [TBL] [Abstract][Full Text] [Related]
6. [Modification of the exocrine pancreas function by octreotide]. Beglinger C Z Gastroenterol; 1990 Sep; 28 Suppl 2():10-1. PubMed ID: 1980770 [No Abstract] [Full Text] [Related]
7. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. Koper JW; Markstein R; Kohler C; Kwekkeboom DJ; Avezaat CJ; Lamberts SW; Reubi JC J Clin Endocrinol Metab; 1992 Mar; 74(3):543-7. PubMed ID: 1346787 [TBL] [Abstract][Full Text] [Related]
8. [Effect of somatostatin and octreotide on exocrine pancreas function and gastrointestinal motility in fasting conditions]. Layer P; von der Ohe M Z Gastroenterol; 1990 Sep; 28 Suppl 2():12-3. PubMed ID: 1980771 [No Abstract] [Full Text] [Related]
9. Somatostatin and the stomach. Ertan A; Arimura A Dig Dis; 1987; 5(1):13-20. PubMed ID: 2885114 [No Abstract] [Full Text] [Related]
10. [Modification of the motility of stomach, intestine and gallbladder by octreotide]. Lembcke B Z Gastroenterol; 1990 Sep; 28 Suppl 2():14-9. PubMed ID: 1980772 [No Abstract] [Full Text] [Related]
11. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Lamberts SW Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931 [TBL] [Abstract][Full Text] [Related]
12. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Afargan M; Janson ET; Gelerman G; Rosenfeld R; Ziv O; Karpov O; Wolf A; Bracha M; Shohat D; Liapakis G; Gilon C; Hoffman A; Stephensky D; Oberg K Endocrinology; 2001 Jan; 142(1):477-86. PubMed ID: 11145612 [TBL] [Abstract][Full Text] [Related]
13. Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism. Viguerie N; Tahiri-Jouti N; Ayral AM; Cambillau C; Scemama JL; Bastié MJ; Knuhtsen S; Estève JP; Pradayrol L; Susini C Endocrinology; 1989 Feb; 124(2):1017-25. PubMed ID: 2563240 [TBL] [Abstract][Full Text] [Related]
14. Human pancreatic cancer cell lines do not express receptors for somatostatin. Gillespie J; Poston GJ; Schachter M; Guillou PJ Br J Cancer; 1992 Sep; 66(3):483-7. PubMed ID: 1355659 [TBL] [Abstract][Full Text] [Related]
15. Are somatostatin analogues (octreotide and lanreotide) effective in promoting healing of enterocutaneous fistulas? Gray M; Jacobson T J Wound Ostomy Continence Nurs; 2002 Sep; 29(5):228-33. PubMed ID: 12510468 [No Abstract] [Full Text] [Related]
16. Effects of somatostatin analogues on human gastrointestinal motility. Camilleri M Digestion; 1996; 57 Suppl 1():90-2. PubMed ID: 8813481 [No Abstract] [Full Text] [Related]
17. Growth-hormone releasing factor does not antagonize somatostatin effects on pancreatic and gastric secretions. Chovet M; Dubrasquet M; Chariot J; Rozé C Experientia; 1985 Nov; 41(11):1451-3. PubMed ID: 2866110 [TBL] [Abstract][Full Text] [Related]